Miltenyi Biomedicine Unveils DALY 2-EU Trial Results for Lymphoma Treatment
Atlanta: Miltenyi Biomedicine has presented the primary analysis of the pivotal DALY 2-EU trial at the 67th American Society of Hematology (ASH) Annual Meeting, showcasing significant findings in the treatment of second-line relapsed/refractory large …